Study using autologous stem cells to treat MS gets FDA OK

08/19/2013 | BioSpectrum Asia · Medical News Today

The FDA has granted Tisch MS Research Center of New York investigational new drug approval to launch a Phase I study to test the use of neural stem cells derived from a patient's own bone marrow to treat multiple sclerosis. "To my knowledge, this is the first FDA-approved stem cell trial in the U.S. to investigate direct injection of stem cells into the cerebrospinal fluid of MS patients, and represents an exciting advance in MS research and treatment," lead researcher Dr. Saud Sadiq said.

View Full Article in:

BioSpectrum Asia · Medical News Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO